State Street SPDR S&P Biotech ETF
Limited financial coverage for XBI.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States.
- IPO
- 2006
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on XBI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.04B
- Div Yield
- 0.38%
- 52W High
- $169.89
- 52W Low
- $103.43
- 50D MA
- $158.21
- 200D MA
- $139.43
- Beta
- 1.10
- RSI (14)
- 46
- Avg Volume
- 8.70M
No earnings-call transcripts are available for XBI yet.
- Free Float
- 0.0%
- Shares Outstanding
- 52.29M
- Float Shares
- 0
of shares held by institutions
1,030 13F filers
Congressional trading
Senate and House stock disclosures for XBI, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas Hawley TubervilleSenate · AL | Buy | May 8, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | May 8, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | May 8, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | May 8, 24 | Filing → |
| James Mountain InhofeSenate · OK | Sell | Sep 30, 19 | Filing → |
| David JoyceHouse · OH14 | Buy | Feb 23, 17 | Filing → |
| James Mountain InhofeSenate · OK | Buy | Dec 31, 18 | Filing → |
| John F. ReedSenate · RI | Sell | Mar 9, 18 | Filing → |
| John F. ReedSenate · RI | Buy | Jun 19, 17 | Filing → |
| John F. ReedSenate · RI | Buy | Mar 6, 17 | Filing → |
| John F. ReedSenate · RI | Buy | Mar 6, 17 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bnp Paribas Arbitrage, Snc | 16.78M | ▼ 4.38M |
| Goldman Sachs Group Inc | 15.11M | ▲ 1.39M |
| Citigroup Inc | 11.61M | ▲ 949.48K |
| Morgan Stanley | 10.83M | ▼ 1.50M |
| Bank Of America Corp | 10.57M | ▼ 3.95M |
| Healthcare Of Ontario Pension Plan Trust Fund | 9.34M | ▼ 404.00K |
| Wells Fargo & Company/Mn | 3.50M | ▲ 757.87K |
| Ubs Group AG | 3.31M | ▼ 237.73K |
| Barclays PLC | 2.82M | ▼ 16.22K |
| Jefferies Financial Group Inc. | 2.14M | ▼ 174.72K |
| Jpmorgan Chase & Co | 1.81M | ▼ 4.43M |
| Canada Pension Plan Investment Board | 1.76M | 0 |
Held by 13 ETFs
Biggest fund positions in XBI by dollar value.
Our XBI coverage
Recent articles, reports, and earnings notes.
Biotech’s breakout is a catalyst trade, not a new market leader
Biotech’s sharp outperformance is real, but the rally is rewarding profitable franchises and identifiable catalysts rather than lifting the entire sector. The better opportunity is selective exposure to de-risked pipelines, not indiscriminate bets on biotech as technology’s replacement.
The rate-cut trade is splitting in two: buy biotech, not every growth stock
A softer July PCE report could revive duration, but the best rebound candidates are profitable, catalyst-backed biotechs rather than every cash-burning growth stock. If inflation keeps yields high, JPM and Goldman offer the more defensible earnings-supported trade.
Want a deeper read on XBI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
SPDR S&P Biotech ETF $XBI Stock Acquired by Ayalon Insurance Comp Ltd.
defenseworld.net · Oct 8
Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech
fool.com · Oct 5
Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals
fool.com · Oct 4
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
zacks.com · Sep 29
VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors?
fool.com · Sep 22
XBI: Big Pharma Can Keep The 76% Rally Going
seekingalpha.com · Sep 5
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
benzinga.com · Sep 1
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
zacks.com · Sep 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.